Mallinckrodt receives FDA approval for Xartemis XR (oxycodone hydrochloride and acetaminophen) extended-release tablets (CII)

17-03-2014 Business Wire HealthComments (0)

BiotechnologyMallinckrodtPharmaceuticalUSAXartemis XR

Mallinckrodt plc (NYSE: MNK) today announced that the US Food and Drug Administration (FDA) has approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), previously known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate. XARTEMIS XR is the first

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top